ACM Biolabs shares positive results from phase 1 SARS-CoV-2 booster vaccine trial
Betsy Goodfellow | September 5, 2023 | News story | Research and Development | ACM Biolabs, COVID-19, Immunology, SARS-CoV-2, Vaccine, clinical trial
ACM Biolabs has announced positive topline results from its phase 1 trial of ACM-001, an adjuvanted booster vaccine for SARS-CoV-2, the virus responsible for COVID-19. ACM-001 is the company’s first clinical-stage development programme.
The booster vaccine utilises a spike-protein component from the immune-evasive beta SARS-CoV-2 variant as well as an immunostimulant, CpG 7909, made via the company’s polymer-based delivery technology, ACM Biolabs’ Tunable Platform (ATP).
The trial demonstrated that the vaccine candidate was safe and well-tolerated at the recommended dose level for both intramuscular injection and mucosal delivery. Early immunogenicity data was promising, suggesting that the vaccine initiated a broadly active antibody response targeting all variants including currently circulating omicron strains.
Further data is expected to be published in the coming months.
Madhavan Nallani, PhD, chief executive officer at ACM Biolabs, commented: “This is excellent news for ACM Biolabs as it substantially de-risks our core technology and enables us to progress all our formulations in discovery and development. We have received a lot of interest in our technology from partners who we believe will find the data valuable as we advance projects with them.”
Pierre Vandepapelière, MD PhD, chief medical officer at ACM Biolabs, stated: “These positive phase 1 results provide clinical validation for ATP, our flexible proprietary delivery platform. It means we can move forward with confidence and explore the full potential of the technology in multiple therapeutic areas including vaccines. What excites us the most is the broader neutralisation upon vaccine administration suggests the high quality of antibodies generated by targeting immune cells. On behalf of ACM, I would like to thank all study participants and staff members at the clinical sites.”
Betsy Goodfellow
Related Content
Tridem begins phase Ib trial of Parkinson’s disease vaccine
Tridem Bioscience has enrolled the first patients in a phase Ib clinical trial of TRB-001, …
How will biomarker-led diagnostics reshape respiratory medicine?
By Dr Louise Ryan Murphy, Chronic obstructive pulmonary disease (COPD) is typically diagnosed and assessed …
AI in pharma: From lab development to patient impact
In the decade to 2025, AI use in vaccine development has increased markedly but is …
